Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 6/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960924 | 0.85 | PDE2A (0.39) | PDE2AMAP3K14F2KLKB1HTR3A | |
| SCHEMBL29333772 | 0.80 | KDM4E (0.43) | HTR3AALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL29333794 | 0.76 | EPHX2 (0.44) | MAP3K14KLKB1HTR3AALDH1A1MGLL | |
| SCHEMBL29334106 | 0.75 | MAPT (0.37) | KLKB1ALDH1A1HSD17B10 | |
| SCHEMBL29333800 | 0.75 | EPHX2 (0.40) | MAP3K14IRAK4KLKB1HTR3AMGLL | |
| SCHEMBL29334059 | 0.73 | TDP1 (0.36) | KLKB1ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL21961388 | 0.71 | F10 (0.41) | MAP3K14MEN1KMT2A | |
| SCHEMBL21960965 | 0.70 | MAP3K14 (0.35) | MAP3K14KLKB1ALDH1A1HPGDMEN1 | |
| SCHEMBL15885600 | 0.70 | PDE4B (0.46) | IRAK4OPRK1ALDH1A1 | |
| SCHEMBL21960911 | 0.69 | LRRK2 (0.39) | IRAK4OPRK1ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | PDE2A 4213/4885MAP3K14 4/4885F2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.